Teva Pharma (TEVA) and Medincell Report Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Teva Pharma (TEVA) and Medincell Report Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749

Teva Pharma (TEVA) PT Raised to $18 at BofA Securities

May 9, 2024 6:16 AM EDT

BofA Securities analyst Jason Gerberry raised the price target on Teva Pharma (NYSE: TEVA) to $18.00 (from $16.00) while maintaining a Buy rating.

The analyst comments "We raise our TEVA PO to $18 (from $16) following positive Phase 3 SOLARIS trial
update for the Olanzapine LAI [long-acting... More